LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Middle East In Vitro Diagnostics Market Worth USD3.4 Billion by 2021

By LabMedica International staff writers
Posted on 14 Oct 2016
Print article
The Middle East market for in vitro diagnostics will be worth USD 3.4 billion by 2021 and record a growth that is one and one-half to double that of the world IVD market. The growth will be driven by expanding populations and a commitment to healthcare spending in this region, which houses offices of most global concerns in Saudi Arabia, Egypt, Dubai or other locales to service this population with testing products and supplies.

These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

In the 1970s, a number of Middle East and Gulf countries began providing public healthcare to their citizens. Currently, Oman, Saudi Arabia, Qatar, Syria and Turkey all have universal healthcare programs.

Lifestyle changes in the Middle East, such as a more sedentary lifestyle that is resulting in rising obesity rates, has led to the emergence of “Western” diseases such as diabetes. This has resulted in a growing demand for medical tests in the region, thus necessitating increased investment in healthcare, which generally takes the form of government tenders that remain a major source of supply for state-controlled labs and hospitals.

IVD companies are focusing strongly on developing countries, where rising incomes and standards of living have created a new health consciousness and growing demand for quality medical care. The opportunity for innovation also exists in the emerging markets, where the acceleration of new products is the largest mid-to-long-term value driver.

"The Middle East remains an underserved region with large market potential," said Bruce Carlson, Publisher of Kalorama Information. "At roughly six percent growth per year, that's far greater where we'd put the overall world market. You should not be surprised to see companies aiming operations there."

The efforts being made by major IVD companies are likely to significantly impact the way Middle Eastern laboratories operate and how they can consistently provide reliable and accurate results to patients. Among the companies targeting the Middle East as a growth region are Roche Diagnostics, Abbott, Siemens Healthcare, Ortho Clinical Diagnostics and Beckman Coulter.

Related Links:
Kalorama Information

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more